Palbociclib in HR-positive, HER2-negative advanced/metastatic breast cancer: A systematic scoping review of real-world evidence from countries outside of Western regions that are underrepresented in clinical trials

Data from certain countries outside of Western regions are underrepresented in clinical trials of palbociclib. To address this, researchers performed a systematic scoping review to compare real-world data from these regions to clinical trial data. After reviewing data from PubMed and Embase, the researchers concluded that the effectiveness and safety profile for palbociclib in real-world settings align with those observed in clinical trials.